Exblifep’s approval was based on the ALLIUM study, which showed that the drug was superior to an older therapy based on piperacillin and tazobactam, achieving clinical cure and microbiological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback